“科技成果+认股权”创新模式，破解科创企业融资难题

Core Insights - The conference held on July 28, 2025, aimed to explore new paths for the integration of innovation and capital in the biopharmaceutical industry, emphasizing high-quality development [1] - The biopharmaceutical sector is characterized by high technology, high risk, and high returns, with traditional financing models often inadequate for its rapid growth [1] - An innovative model combining "technology achievements + stock options" is proposed to address financing challenges faced by companies in this sector [1] Financing Innovations - The Guangdong Equity Exchange Center suggests that stock options can be innovatively combined with financial products to assess the value of patent technology and corporate equity [3] - This model allows banks to provide loans to tech companies while obtaining stock options, enabling them to share in the equity appreciation as the companies grow [3] - The introduction of stock option loans offers tech companies lower financing thresholds and costs, while allowing founders to maintain control over their businesses [3] Risk Mitigation Strategies - The stock option loan business can incorporate intellectual property pledges as part of the credit conditions, aligning with local financing risk compensation policies [3] - This approach aims to reduce project risks and financing costs for companies, while also facilitating follow-up financing through option execution and bank renewals [3]